Precision Biosciences Stock Price, News & Analysis

Precision BioSciences (NASDAQ: DTIL) announced the acceptance of its abstract titled “Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine” for presentation at the SITC 36th Annual Meeting from November 10-14, 2021, in Washington, D.C. The study highlights a preclinical advancement using ARCUS gene editing to develop fludarabine-resistant CAR T cells, with a notable 70% reduction in dCK mRNA and improved tumor clearance in mice. The findings may enhance the potential of CAR T therapies in treating cancers resistant to conventional treatments.

Precision BioSciences (NASDAQ: DTIL) announced the addition of two experienced directors, Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D., to its Board. These appointments enhance the board's expertise in gene therapy and operational leadership. Dr. Wadsworth has nearly 30 years of experience in gene therapy development, while Ms. Piré brings extensive legal and business transformation skills. The company aims to advance three INDs/CTAs in the next three years, marking a significant phase in its growth strategy.

Precision BioSciences (NASDAQ: DTIL) has announced encouraging results from its Phase 1/2a study of PBCAR0191, targeting relapsed/refractory non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). Enhanced lymphodepletion strategy improved the overall response rate (83%) and complete response rate (CR) among heavily pretreated subjects. Data will be presented at the ASH Annual Meeting on December 11-14, 2021. Notably, 80% of B-ALL patients responded positively, indicating potential for bridging to stem cell transplant.

Precision BioSciences, Inc. (DTIL) announced it will publish its financial results for Q3 2021 on November 10, 2021, and provide a business update. CEO Michael Amoroso will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021. The company utilizes its ARCUS® genome editing platform for developing CAR T and in vivo gene editing therapies targeting genetic and infectious diseases. Investors can access a live webcast of the chat on the company’s website.

Precision BioSciences, Inc. (NASDAQ: DTIL) announced that Dr. Derek Jantz, Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit on October 27, 2021, from 1:30 to 1:55 ET. The company reported a cash balance of approximately $160.5 million as of September 30, 2021, expected to support operations into 2023. The presentation will be available via webcast on the company’s investor website, with an archived replay for about 30 days.

Precision BioSciences, a clinical-stage biotech company (NASDAQ: DTIL), announced an inducement grant for Michael Amoroso, its new President and CEO. The grant includes options to purchase 850,000 shares and restricted stock units valued at $237,000. The stock option has a 10-year term, with 25% vesting on October 15, 2022, and the remainder vesting quarterly over three years. Both awards comply with the company's 2021 Employment Inducement Incentive Award Plan, approved by the Compensation Committee.

Precision BioSciences (NASDAQ: DTIL) announced Michael Amoroso as the new President and CEO, effective October 15, 2021, succeeding Co-Founder Matt Kane. Amoroso brings extensive experience in operational management and commercial roles within gene and cell therapies, particularly in oncology. His leadership is expected to enhance the company's ARCUS genome editing platform and advance late-stage clinical strategies. The Board of Directors commended Kane's significant contributions to the company.

Precision BioSciences (DTIL), a clinical-stage biotechnology company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The pre-recorded presentation will be available for on-demand viewing on September 13, 2021, at 7:00 a.m. ET on the company’s website. Precision BioSciences focuses on developing allogeneic CAR T and in vivo gene correction therapies using its proprietary ARCUS® genome editing platform, targeting genetic and infectious diseases with its innovative pipeline.

Precision BioSciences (DTIL) has accelerated its clinical development, expecting three new drug applications within three years targeting familial hypercholesterolemia, primary hyperoxaluria type 1, and chronic hepatitis B. A licensing agreement with iECURE aims to advance PBGENE-PCSK9 through Phase 1 trials, while preclinical data showcases their ARCUS genome editing platform's precision. The company has approximately $167 million in cash, sufficient to fund operations into 2023.